Apyx Medical opened lower at $2.93, compared with its previous close of $3.00. In the last trading session, the stock traded between $2.77 and $2.93. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Apyx Medical is now worth
$ 19.86
Resulting in a loss of
$ 80.14 (80.14%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.10 (-3.33%)
Day High
$2.93
Day Low
$2.77
Day Open
$2.93
Prev Close
$3.00
Volume
1,14,038
1W Return
12.45%
1M Return
8.49%
3M Return
-3.49%
6M Return
-26.02%
1Y Return
-27.50%
Fundamentals
Market Cap ($ Mn)
122
PE Ratio
-
PB Ratio
12.17
PEG Ratio
-
ROE
-106.04%
ROCE
-12.51%
EPS (TTM)
$-0.04
Investment Returns
1 Week
12.45%
1 Month
8.49%
3 Months
-3.49%
6 Months
-26.02%
9 Months
-26.02%
Financials
Quarterly
All values in $ Mn
11.4
Jun 25
12.9
Sep 25
19.2
Dec 25
12.5
Mar 26
13.9
Jun 26
14.0
Sep 26
Updates
5Nov
Apyx Medical FY26 Results: Sales guidance affirmed at $59M-$60M
Apyx Medical Corporation affirms FY2026 sales guidance of $59.0 million to $60.0 million. The guidance range remains unchanged from previous projections. Analyst estimates for FY2026 sales stand at $59.41 million. The company's forecast midpoint is $59.5 million, closely tracking consensus.
7 days ago
7Aug
Apyx Medical Q2 Results: EPS, Sales Beat Estimates
Apyx Medical beat Q2 estimates with EPS of $(0.07) and sales of $13.884M. Losses narrowed 22.22% YoY, while revenue surged 22.08%, signaling strong operational momentum despite ongoing unprofitability.
3mo ago
7Aug
Apyx Medical Latest Results: Sales guidance affirmed at $59-60M
Apyx Medical reaffirms its FY2026 sales guidance of $59.000 million to $60.000 million, matching prior expectations and aligning with the $59.554 million market estimate. The stable outlook reflects confidence in the company's operational performance for the fiscal year.
3mo ago
13Jul
HC Wainwright initiates Apyx Medical coverage with Buy rating
HC Wainwright & Co. analyst Yi Chen initiated coverage on Apyx Medical with a Buy rating and a price target of $7, signaling a positive outlook.
4mo ago
18Jun
Apyx Medical appoints Stavros Vizirgianakis executive chairman
Apyx Medical has appointed Stavros Vizirgianakis as Executive Chairman, effective June 11. The company disclosed the leadership change in a Form 8-K filing with the U.S. Securities and Exchange Commission.
